Some recent studies have also shown an association between high baseline IL-6 levels and reduced benefits from immunotherapy in hepatocellular carcinoma, melanoma, renal cell carcinoma, lung cancer and cutaneous squamous cell carcinoma patients [14, 19–22]. Here, IL6 is linked to lung carcinoma.